⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,823.50
−0.19%
FTSE ADX
9,790.47
−0.40%
TASI
9,952.06
−1.69%
QE Index
8,658.85
+0.70%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,704.40
−0.81%
Sensex
73,360.48
−0.67%
KSE-100
165,671.54
+0.31%
DFM:EMIRATESNBD
AED 31.60
+0.06%
ADX:IHC
AED 353.80
−0.79%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.54
−0.06%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,209.60
+0.63%
KAR:OGDC
Rs 300.48
+0.16%
Gold
$4,114.39
−0.27%
Brent
$110.16
+0.98%
BTC
$82,671.58
−0.33%
ETH
$2,438.72
−0.33%
DFM General
5,823.50
−0.19%
FTSE ADX
9,790.47
−0.40%
TASI
9,952.06
−1.69%
QE Index
8,658.85
+0.70%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,704.40
−0.81%
Sensex
73,360.48
−0.67%
KSE-100
165,671.54
+0.31%
DFM:EMIRATESNBD
AED 31.60
+0.06%
ADX:IHC
AED 353.80
−0.79%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.54
−0.06%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,209.60
+0.63%
KAR:OGDC
Rs 300.48
+0.16%
Gold
$4,114.39
−0.27%
Brent
$110.16
+0.98%
BTC
$82,671.58
−0.33%
ETH
$2,438.72
−0.33%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Open
🇸🇦
Saudi Arabia
Tadawul · TASI
Open
🇶🇦
Qatar
QSE · QE General
Open
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Open
🇵🇰
Pakistan
PSX · KSE-100
Open
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› AVBP
A
ArriVent BioPharma Inc
NAS:AVBP
Healthcare
CBOEFTSE:MRUT
NASDAQ:NBI
$18.85
+5.07%
At close
At close · Wed 21 Oct · ≈
AED 69.23
· Market cap
$929.45M
· Next earnings
Mon 9 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
ArriVent BioPharma Inc · News · TradingHolo
AVBP news
Headlines tagged to this company
TR
Arri Announces Cancer Cell Publication Showing Strong Phase 1b Activity for Firmonertinib in EGFR PACC NSCLC
TradingView · 2 d ago
TR
ArriVent BioPharma, Inc. (AVBP) Publishes Phase 1b Data on Firmonertinib in PACC-Mutant NSCLC
TradingView · 2 d ago
TR
BTIG reiterates Buy rating on ArriVent BioPharma, $29 price target
TradingView · 5 d ago
TR
ArriVent doses first patient in U.S. Phase 1 trial of ARR-002 dual-target ADC
TradingView · 8 d ago
RE
Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
Reuters · 8 d ago
TR
ArriVent BioPharma, Inc. (AVBP) Doses First Patient in ARR-002 Phase 1 Trial
TradingView · 9 d ago
DO
ArriVent BioPharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones Newswires · 13 d ago
TR
HC Wainwright & Co. maintains Buy rating on ArriVent BioPharma, $27 price target
TradingView · 13 d ago
DO
ArriVent BioPharma Is Maintained at Buy by Citigroup
Dow Jones Newswires · 14 d ago
DO
ArriVent BioPharma Is Maintained at Buy by Jones Trading
Dow Jones Newswires · 14 d ago
PR
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
PR Newswire · 14 d ago
PR
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
PR Newswire · 14 d ago
DO
ArriVent BioPharma Price Target Cut to $18.00/Share From $45.00 by Truist Securities
Dow Jones Newswires · 14 d ago
DO
ArriVent BioPharma Price Target Cut to $18.00/Share From $45.00 by Guggenheim
Dow Jones Newswires · 14 d ago
TR
Guggenheim maintains Buy rating on ArriVent BioPharma, $18 price target
TradingView · 14 d ago
DO
ArriVent BioPharma Price Target Cut to $29.00/Share From $42.00 by BTIG
Dow Jones Newswires · 14 d ago
TR
BTIG maintains Buy rating on ArriVent BioPharma, $29 price target
TradingView · 14 d ago
TR
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside
TradingView · 14 d ago
ST
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
Stocktwits · 15 d ago
DO
Why This Biotech Stock Is Having Its Worst Day Ever — Barrons.com
Dow Jones Newswires · 15 d ago
More news →